MINI FUTURE LONG - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 01:20:29 04/07/2024 am IST | ||
| 56.08 EUR | -1.98% |
|
| Current month | -2.47% | ||
| 1 month | +13.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 56.08 | -1.98% |
| 02/24/02 | 57.21 | -1.26% |
| 01/24/01 | 57.94 | +0.77% |
| 28/24/28 | 57.5 | +0.28% |
| 27/24/27 | 57.34 | +0.61% |
Delayed Quote Deutsche Boerse AG
Last update July 04, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PD49MK |
| ISIN | DE000PD49MK8 |
| Date issued | 27/04/2022 |
| Strike | 293.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.23 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 58.21 € |
|---|---|
| Lowest since issue | 2.92 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Certificates
- Certificat
